Monday, December 2, 2019

Puma Biotechnology Extends License Deal

Los Angeles-based biopharmaceuticals developer Puma Biotechnology, which is developing treatments for breast cancer, says it has extended a license agreement it has with Pierre Fabre, to cover commercial rights in the Middle East, South Africa, Sudan, and Turkey. Pierre Fabre already had the exclusive rights to develop and commercialize its lead compound, NERLYNX, within Europe and parts of Africa. According to Puma, it will receive an upfront payment of $4 million, as well as additional regulatory and sales-based milestone payments totaling up to $3 million, for the extension of the license.

---